0001299130trueDEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.00012991302025-01-242025-01-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
January 24, 2025
Pacific Biosciences of California, Inc.
(Exact name of registrant as specified in its charter)
Delaware001-3489916-1590339
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
1305 O’Brien Drive
Menlo Park, California 94025
(Address of principal executive offices) (Zip Code)
(650) 521-8000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per sharePACBThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

Pacific Biosciences of California, Inc. (the “Company”) is filing this amendment to its Current Report on Form 8-K filed on January 30, 2025, which reported that the Company’s Board of Directors (the “Board”) had appointed Christopher M. Smith as a new director of the Company. At the time of his appointment, Mr. Smith was not appointed to any Board committee. On February 6, 2024, upon the recommendation of the Corporate Governance and Nominating Committee of the Board, the Board appointed Mr. Smith to the Science and Technology Committee of the Board, effective immediately. In connection with his appointment to the Science and Technology Committee, Mr. Smith will receive additional cash compensation as set forth in the Company’s non-employee director compensation policy, as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2024. Concurrent with such appointment, upon the recommendation of the Corporate Governance and Nominating Committee of the Board, the Board appointed Marshall Mohr as chairman of the Audit Committee of the Board in place of Randy Livingston, who will continue to serve as a member of the Audit Committee.



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Pacific Biosciences of California, Inc.
By:/s/ Brett Atkins
Brett Atkins
General Counsel
Date: February 7, 2025

v3.25.0.1
Cover Page
Jan. 24, 2025
Cover [Abstract]  
Document Type 8-K/A
Document Period End Date Jan. 24, 2025
Entity Registrant Name Pacific Biosciences of California, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-34899
Entity Tax Identification Number 16-1590339
Entity Address, Address Line One 1305 O’Brien Drive
Entity Address, City or Town Menlo Park
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94025
City Area Code 650
Local Phone Number 521-8000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol PACB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001299130
Amendment Flag true
Document Information [Line Items]  
Document Period End Date Jan. 24, 2025
Amendment Description DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Pacific Biosciences of C... Charts.
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Pacific Biosciences of C... Charts.